Specifications
- 1 ml at 5 mg/ml
- CYP1A characterization
Description
Our human lung S9 fraction offers a versatile in vitro system for evaluating Phase I metabolism in pulmonary tissue. Isolated from non-diseased human lung tissue, the S9 fraction contains both microsomal and cytosolic enzymes, enabling comprehensive assessment of drug biotransformation pathways. This product is ideal for studying inhaled drug metabolism, extrahepatic clearance, and respiratory toxicology in preclinical research and drug development.

